Get to know our clinical trials
Clinical trial to investigate the efficacy, safety and tolerability of remibrutinib (LOU064) in chronic inducible urticaria (CINDU) in adults inadequately controlled with H1 antihistamines.
THE AIM OF THE STUDY IS TO FIND OUT WHETHER REMIBRUTINIB IS SAFE AND TO WHAT EXTENT IT IS TOLERATED BY THE BODY AND TO STUDY WHETHER IT HAS THE DESIRED EFFECT IN THE TREATMENT OF CHRONIC INDUCIBLE URTICARIA IN ADULTS TAKING ANTIHISTAMINES.
Status
In recruitment
headquarters
Pamplona/Madrid
Technical Summary
- A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPEN-LABEL, OPEN-LABEL, DOUBLE-BLIND BASKET STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF REMIBRUTINIB (LOU064) IN CHRONIC INDUCIBLE URTICARIA (CINDU) IN ADULTS INADEQUATELY CONTROLLED WITH H1 ANTIHISTAMINES.
- Code EudraCT: 2023-505739-12
- Protocol number: CLOU064M12301
- Promoter: Novartis Farmaceutica
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.